Rigel Pharmaceuticals (RIGL) News Today $20.13 +2.78 (+16.02%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Equities Analysts Set Expectations for RIGL Q4 EarningsJanuary 18 at 2:24 AM | americanbankingnews.comShort Interest in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Rises By 27.1%Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) saw a large increase in short interest in December. As of December 31st, there was short interest totalling 807,500 shares, an increase of 27.1% from the December 15th total of 635,400 shares. Approximately 4.7% of the company's stock are sold short. Based on an average daily trading volume, of 243,900 shares, the days-to-cover ratio is currently 3.3 days.January 17 at 10:10 PM | marketbeat.comHC Wainwright Has Bullish Estimate for RIGL Q4 EarningsRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Research analysts at HC Wainwright boosted their Q4 2024 earnings estimates for Rigel Pharmaceuticals in a note issued to investors on Tuesday, January 14th. HC Wainwright analyst J. Pantginis now forecasts that the biotechnology company wJanuary 17 at 7:05 AM | marketbeat.comCantor Fitzgerald Brokers Raise Earnings Estimates for RIGLJanuary 17 at 1:13 AM | americanbankingnews.comCantor Fitzgerald Analysts Boost Earnings Estimates for RIGLRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Equities researchers at Cantor Fitzgerald lifted their FY2024 earnings estimates for Rigel Pharmaceuticals in a research report issued to clients and investors on Tuesday, January 14th. Cantor Fitzgerald analyst K. Kluska now forecasts thaJanuary 16 at 6:34 AM | marketbeat.comStrong Commercial Performance and Promising Pipeline Drive Rigel’s Buy RatingJanuary 14, 2025 | markets.businessinsider.comRigel Pharmaceuticals sees Q4 revenue $57.6M, consensus $47.42MJanuary 14, 2025 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Rigel Pharmaceuticals (NASDAQ:RIGL)HC Wainwright reaffirmed a "buy" rating and issued a $57.00 price objective on shares of Rigel Pharmaceuticals in a research note on Tuesday.January 14, 2025 | marketbeat.comRigel Pharmaceuticals Reports Preliminary Q4 Results; Issues 2025 OutlookJanuary 13, 2025 | markets.businessinsider.comRigel Provides Business Update and 2025 OutlookJanuary 13, 2025 | prnewswire.comRigel announces R289 granted Orphan Drug designation by FDA for MDSJanuary 10, 2025 | markets.businessinsider.comRigel Pharmaceuticals, Inc.: Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDSJanuary 9, 2025 | finanznachrichten.deRigel Pharmaceuticals Gets FDA Orphan-Drug Designation for R289January 9, 2025 | marketwatch.comRigel Pharma: FDA Grants Orphan Drug Designation To R289 - Quick FactsJanuary 9, 2025 | markets.businessinsider.comRigel Announces R289 Granted Orphan Drug Designation by the FDA for MDSJanuary 9, 2025 | prnewswire.comRigel to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | prnewswire.comJane Street Group LLC Sells 80,271 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Jane Street Group LLC cut its position in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 75.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,589 shares of the biotechnology company'January 8, 2025 | marketbeat.comRigel granted orphan status for myelodysplastic syndromes treatmentJanuary 7, 2025 | markets.businessinsider.comRigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)January 3, 2025 | prnewswire.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Rating of "Hold" from BrokeragesRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) has been given a consensus rating of "Hold" by the five research firms that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and two have given a buy reJanuary 3, 2025 | marketbeat.comRigel Pharmaceuticals: Realizing The Promise Of Its Acquired Pipeline AgentsDecember 30, 2024 | seekingalpha.comRigel Pharmaceuticals (NASDAQ:RIGL) Stock Crosses Above 200 Day Moving Average - Here's What HappenedRigel Pharmaceuticals (NASDAQ:RIGL) Share Price Crosses Above 200 Day Moving Average - What's Next?December 26, 2024 | marketbeat.comShould You Buy the Dip on Rigel Pharmaceuticals (RIGL)?December 16, 2024 | wallstreetzen.comRecent 26% pullback isn't enough to hurt long-term Rigel Pharmaceuticals (NASDAQ:RIGL) shareholders, they're still up 50% over 1 yearDecember 12, 2024 | finance.yahoo.comRigel Pharmaceuticals price target raised to $25 from $15 at Cantor FitzgeraldDecember 11, 2024 | markets.businessinsider.comRigel Pharmaceuticals price target lowered to $20 from $27 at B. RileyDecember 11, 2024 | markets.businessinsider.comRigel Pharmaceuticals announces initial data from Phase 1b study of R289December 10, 2024 | markets.businessinsider.comRigel Pharmaceuticals (NASDAQ:RIGL) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $57.00 price objective on shares of Rigel Pharmaceuticals in a research note on Tuesday.December 10, 2024 | marketbeat.comRigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and ExpositionDecember 9, 2024 | prnewswire.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Rating of "Hold" from AnalystsShares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) have been given an average rating of "Hold" by the five brokerages that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and two have assigned a buy ratinDecember 9, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Sells 60,913 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Jacobs Levy Equity Management Inc. reduced its stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 25.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 177,340 shares of the biotechnology company's stock after selling 60December 8, 2024 | marketbeat.comB. Riley Issues Positive Forecast for Rigel Pharmaceuticals (NASDAQ:RIGL) Stock PriceB. Riley upped their target price on Rigel Pharmaceuticals from $17.00 to $27.00 and gave the stock a "neutral" rating in a research note on Friday.December 6, 2024 | marketbeat.comRigel Pharmaceuticals price target raised to $27 from $17 at B. RileyDecember 6, 2024 | tipranks.comPDT Partners LLC Acquires New Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)PDT Partners LLC bought a new stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 19,914 shares of the biotechnology company's stock, valued at apDecember 4, 2024 | marketbeat.comRigel Pharmaceuticals, Inc.: Rigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDSDecember 2, 2024 | finanznachrichten.deRigel Pharmaceuticals announces R289 granted Fast Track designation by FDADecember 2, 2024 | tipranks.comRigel Announces R289 Granted Fast Track Designation by the FDA for Lower-Risk MDSDecember 2, 2024 | prnewswire.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Significant Decline in Short InterestRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) was the recipient of a significant decrease in short interest during the month of November. As of November 15th, there was short interest totalling 462,700 shares, a decrease of 30.0% from the October 31st total of 661,200 shares. Approximately 2.7% of the company's stock are sold short. Based on an average daily trading volume, of 198,500 shares, the short-interest ratio is currently 2.3 days.November 29, 2024 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Stock Holdings Lifted by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 29.7% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 98,006 shares of thNovember 27, 2024 | marketbeat.comZacks.com featured highlights Rigel, Synchrony Financial, SkyWest, Allient and Rush Street InteractiveNovember 19, 2024 | finance.yahoo.comRigel (RIGL) Receives a Hold from Piper SandlerNovember 15, 2024 | markets.businessinsider.comLos Angeles Capital Management LLC Increases Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Los Angeles Capital Management LLC boosted its stake in shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 34.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 74,502 shares of the biotechnologNovember 15, 2024 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of "Moderate Buy" by AnalystsRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) has earned an average recommendation of "Moderate Buy" from the four analysts that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and two have assignedNovember 14, 2024 | marketbeat.comPiper Sandler Forecasts Strong Price Appreciation for Rigel Pharmaceuticals (NASDAQ:RIGL) StockPiper Sandler raised their target price on shares of Rigel Pharmaceuticals from $15.00 to $23.00 and gave the stock a "neutral" rating in a report on Thursday.November 14, 2024 | marketbeat.comRigel Pharmaceuticals price target raised to $49 from $40 at CitiNovember 13, 2024 | markets.businessinsider.comRigel to Present at the Jefferies London Healthcare ConferenceNovember 12, 2024 | prnewswire.comRigel’s Robust Financial Performance and Strategic Partnerships Drive Buy RatingNovember 10, 2024 | markets.businessinsider.comRigel Pharmaceuticals Reports Strong Q3 2024 ResultsNovember 9, 2024 | markets.businessinsider.comRigel stock rallies 36% after Q3 earnings beatNovember 9, 2024 | msn.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | insidermonkey.com Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address RIGL Media Mentions By Week RIGL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RIGL News Sentiment▼0.590.55▲Average Medical News Sentiment RIGL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RIGL Articles This Week▼203▲RIGL Articles Average Week Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Innoviva News OPKO Health News Ironwood Pharmaceuticals News Emergent BioSolutions News Codexis News XOMA News Vanda Pharmaceuticals News Verastem News Sangamo Therapeutics News Lexicon Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RIGL) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rigel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RIGL Stock Alerts